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Kawasaki disease (KD) is a systemic vasculitis of unknown etiology. Absence of
deﬁnitive diagnostic markers limits the accuracy of clinical evaluations of
suspected KD with signiﬁcant increases in morbidity. In turn, incomplete under-
standing of its molecular pathogenesis hinders the identiﬁcation of rational
targets needed to improve therapy. We used high-accuracy mass spectrometry
proteomics to analyse over 2000 unique proteins in clinical urine specimens of
patients with KD. We discovered that urine proteomes of patients with KD, but
not those with mimicking conditions, were enriched for markers of cellular injury
such as ﬁlamin and talin, immune regulators such as complement regulator
CSMD3, immune pattern recognition receptor muclin, and immune cytokine
proteasemeprinA. Signiﬁcant elevationsof ﬁlaminC andmeprinAweredetected
in both the serum and urine in two independent cohorts of patients with KD,
comprised of a total of 236 patients. Meprin A and ﬁlamin C exhibited superior
diagnostic performance as compared to currently used markers of disease in a
blinded case-control study of 107 patients with suspected KD, with receiver
operating characteristic areas under the curve of 0.98 (95% conﬁdence intervals
[CI] of 0.97–1 and 0.95–1, respectively). Notably, meprin A was enriched in the
coronary artery lesions of a mouse model of KD. In all, urine proteome proﬁles
revealed novel candidate molecular markers of KD, including ﬁlamin C and
meprin A that exhibit excellent diagnostic performance. These disease markers
may improve the diagnostic accuracy of clinical evaluations of children with
suspected KD, lead to the identiﬁcation of novel therapeutic targets, and allow
the development of a biological classiﬁcation of Kawasaki disease.
INTRODUCTION
Kawasaki disease (KD) or mucocutaneous lymph node
syndrome is an acute, systemic vasculitis of children that
presents with prolonged fever and mucocutaneous inﬂamma-
tion, including inﬂammation of the oral mucosa, non-exudative
conjunctivitis, rash, extremity changes and cervical lymphade-
nopathy that is usually unilateral (Burns et al, 1991). Although
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in American and European populations, it is the most common
cause of acquired paediatric heart disease in the developed
world and remains a major medical problem because its
signs and symptoms mimic many other childhood febrile
illnesses (Baker et al, 2009; Taubert et al, 1991). In addition,
the prevalence of KD is particularly high in Asia; 1 in
100 Japanese children under the age of 5 years develop
Kawasaki disease (Nakamura et al, 2010).
Delays in accurate diagnosis lead to increased mortality and
morbidity from complications of Kawasaki disease (Suda et al,
2011; Wilder et al, 2007). In particular, without timely
treatment, as many as 25% of patients may develop coronary
artery dilatation or aneurysms, with the associated risk of long-
termmorbidity ordeath(McCrindleetal, 2007).Importantly, no
pathognomonic test exists for the early identiﬁcation and
diagnosis of KD (Dedeoglu & Sundel, 2007; Gedalia, 2007). The
use of clinical algorithms has improved the diagnosis of
Kawasaki disease, but their accuracy remains limited (Yellen
et al, 2010).
Attempts to improve the reliability of clinical evaluations of
Kawasaki disease have focused on clinical and general
laboratory markers of inﬂammation (Chow et al, 1993; Ebihara
et al, 2005; Lin et al, 1992; Peng et al, 2006; Suganami et al,
2008).However,theirperformanceisinadequate,likelybecause
of their non-speciﬁc relationship to the pathophysiology of
KD, which is thought to be caused by an interaction between an
infectious trigger and an exaggerated inﬂammatory response
(Rowley et al, 2008).
In the current study, we employed a discovery-based
approach, seeking to identify these pathophysiological altera-
tions on a proteomic scale. We studied urine because of its
abundance and relative analytic simplicity as compared to
serum. Previously, we and others have successfully used high
accuracy mass spectrometry to measure urine proteomes with
sufﬁcientdepthtoidentifylocalandsystemicbiomarkers,andto
discover improved diagnostic markers of disease (Adachi et al,
2006; Kentsis et al, 2010; Oetting et al, 2006; Pisitkun et al, 2006;
Rai et al, 2005; Woroniecki et al, 2006; Zimmerli et al, 2008).
The goal of our study was to discover and validate diagnostic
markers of Kawasaki disease in a prospective paediatric cohort.
By usinghigh accuracy mass spectrometry proteome proﬁling of
urine specimens collected from children with suspected KD,
we analysed the differences in individual urine proteomes.
Candidate diagnostic markers were validated in the urine and
serum in two independent cohorts of patients with KD using
enzyme-linked immunosorbent assays (ELISAs). Their diag-
nostic performance was then assessed in a blinded, prospective
study of children with suspected KD.
RESULTS
Mass spectrometry proteomics for discovery of Kawasaki
disease markers
During the course of this study, we enrolled 107 subjects who
presented with fever and concern for possible KD, based on
established diagnostic criteria (Newburger et al, 2004). In
agreement with previous studies of the epidemiology and
presentation of KD, our study population was predominantly
male, with a mean age of 3 years and with the presenting signs
and symptoms described in Table 1. Fifty-three patients (49%)
were ultimately diagnosed with KD. All patients with KD
received treatment with high-dose aspirin and intravenous
gammaglobulin, with 16 patients (30%) requiring repeat
treatment due to lack of initial clinical response, including
one patient (2%) who initially responded to therapy but
developed recurrent disease 5.5 months following initial
presentation. Thirty-three of 54 patients without Kawasaki
disease (61%) were found to have non-speciﬁc viral syndrome,
withtheremainingpatientsfoundtohaveavarietyofconditions
that may mimic KD (Table 2).
Candidate diagnostic markers of KD were identiﬁed based on
the analysis of 15 specimens collected at the onset of the study
and chosen based on availability: 6 KD specimens (3 without
and 3 with coronary artery dilatation), 6 non-KD specimens
(2 with non-speciﬁc viral syndromes, 3 with adenovirus, and 1
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Table 1. Presenting signs, symptoms and diagnostic studies of 107
patients with suspected of Kawasaki disease
Characteristic Final diagnosis
Non-KD
n¼54
KD
n¼53
Gender (% male)
c 27 (50) 39 (73)
Race (%)
Caucasian 38 (70.3) 28 (52.8)
African American 4 (7.4) 3 (5.6)
Asian
c 4 (7.4) 12 (22.6)
Other 8 (14.8) 7 (20.1)
Age (years)
c 5 [3.3,6.7] 3.3 [1.8,5]
Duration of fever, days 6 [5,7] 6 [5,7]
Number of primary criteria
a,b,c 2 [1,3] 4 [4,5]
Conjunctivitis (%)
c 31 (57) 51 (96)
Mucositis (%)
c 24 (44) 51 (96)
Rash (%)
c 31 (57) 51 (96)
Extremity changes (%)
c 14 (26) 45 (85)
Lymphadenopathy (%)
c 12 (22) 28 (53)
Pyuria (%)
c 5 (9.8) 16 (30)
Peripheral WBC (K cells/mm
3)
c 8.8 [6.5,12.7] 14.7 [12,17]
Hgb (g/dl)
c 11.6 [11.1,12.2] 10.7 [10,11.5]
Platelet (K cells/mm
3)
c 297 [215,351] 402 [345,478]
Na (mmol/L) 135 [133,137] 134 [132,135.5]
CRP (mg/dl)
c 4.9 [2.2, 8.3] 9.2 [6.3, 16.7]
ESR (mm/h)
c 44 [27.8, 69] 86 [61,96.3]
ALT (unit/L)
c 16 [11.5, 33] 28 [14,104.5]
Albumin (g/dl)
c 3.8 [3.6, 4] 3.5 [3.3, 3.8]
Maximum coronary artery Z-score n/a 1.4 [0.8, 1.9]
Incomplete presentation
b (%) n/a 11 (20.7)
Values are reported as frequency (percent) or median [IQR], where appropriate.
aPrimary criteria: fever  5 days, conjunctivitis, oropharyngeal ﬁndings, rash,
extremity changes, adenopathy.
bIncomplete presentation (see text for description); Hgb, hemoglobin; Na,
sodium; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ALT,
alanine aminotransferase. Pyuria was deﬁned as having >10 white blood
cells/high-powered ﬁeld.
cDifference between KD and non-KD groups statistically signiﬁcant (p<0.05).
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patients with KD 1 month following complete response to
treatment (convalescent KD). This analysis identiﬁed 2131
unique proteins, with the tissue and physical origin of the
aggregate urine proteomes similar to previous studies (Kentsis
et al, 2009). Analysis of the three comparison groups led to the
identiﬁcation of more than 190 proteins in the urine of patients
with KD, but not in any of the patients without KD or in those
whose KD had resolved completely (Supporting Information
Table 1). We analysed the abundance of candidate KD markers
to identify those that are most enriched in patients with KD,
ranking them in order of relative abundance and prevalence
(Fig 1). The identiﬁed markers include a variety of proteins
associated with endothelial and myocardial cell injury such as
ﬁlamin and titin, and immune regulators such as DMBT1 and
meprin A. Many of the detected markers are high molecular
weight proteins, which are probably enriched in the urine of
patients with KD as processed and/or truncated proteins, as
conﬁrmed for meprin A and ﬁlamin C by Western immunoblot-
ting (Fig 1A). The discovered proteomes are provided in
Supporting Information Table 2 (processed data), and the raw
data, in accordance with the MIAPE standard, and are openly
available at Peptide Atlas (http://www.peptideatlas.org).
Validation of filamin C and meprin A using immunoassays
In order to validate selected candidate KD markers, we chose to
analyse the levels of ﬁlamin C and meprin A because of their
biological functions that may play a role in KD vide infra and
because of availability of commercial ELISAs. We chose to
validate candidate markers in urine because of its availability.
To assess the KD diagnostic performance of ﬁlamin C and
meprin A, we prospectively measured their concentrations in
the urine of patients, with investigators blinded to the patients’
ﬁnal diagnosis. Patients studied as part of the discovery phase of
our study were not included in this validation. We did not
ﬁnd statistically signiﬁcant differences in total urine protein
concentration in the cohort under study (Supporting Informa-
tion Fig 1). However, urine concentrations of both meprin A
and ﬁlamin C were signiﬁcantly elevated in patients with KD as
compared to those without, even when corrected for variability
in total urine concentration based on urine creatinine (mean
ﬁlamin C of 19.2 vs. 3.7ng/ml, and mean meprin A of 50.2 vs.
5.6ng/ml, two-tailed t-test p¼2.0E 8 and 1.3E 17, respec-
tively, Fig 2A and B, Supporting Information Table 3).
Controlling for age, sex, race and duration of fever using
logistic regression did not affect the statistical signiﬁcance of the
elevations of meprin A and ﬁlamin C. Notably, we found that
urine meprin A and ﬁlamin C were also signiﬁcantly elevated in
patients with incomplete presentations of KD, meeting only
three out of four major diagnostic criteria, as compared to those
without KD (mean ﬁlamin C of 17.0 vs. 3.7ng/ml, and mean
meprin A of 41.5 vs. 5.6ng/ml, two-tailed t-test p¼2.7E 6 and
2.2E 6, respectively).
Diagnostic performance of validated markers of Kawasaki
disease
We analysed the diagnostic performance of meprin A and
ﬁlamin C for all patients in the validation cohort using receiver
operating characteristic (ROC) analysis. The ROC curves for
these markers exhibited superior diagnostic performance as
compared to the currently used laboratory markers such as the
erythrocyte sedimentation rate (ESR) and blood C-reactive
protein (CRP), with urine creatinine-normalized meprin A and
ﬁlamin C having an area under the curve value of 0.98 with 95%
conﬁdence intervals of 0.97–1 and 0.95–1, respectively (Fig 2C
and D). The diagnostic performance of either urine meprin A or
ﬁlamin C was superior to that of ESR, CRP or the combination of
CRP/ESR (Fig 2D). The combination index of ﬁlamin C and
meprin A did not lead to statistically signiﬁcant improvements
over the use of individual markers alone (FlnC/MepA; Fig 2D).
Notably, urine meprin A and ﬁlamin C concentrations did not
correlate with the presence of pyuria, CRP or ESR (Supporting
Information Figs 1–5).
In addition, we assessed the relationship between meprin A
and ﬁlamin C and response to therapy, by measuring their
urine concentrations in matched serial specimens. These were
collected at diagnosis prior to initiation of therapy, 24–48h after
treatment with high dose aspirin and intravenous gammaglo-
bulin, and 1 month after complete clinical response to treatment
in ﬁve patients for whom matched specimens could be
collected. In all patients studied, urine meprin A and ﬁlamin
Clevelscorrelatedwithresponsetotreatment(one-wayANOVA
p¼0.043 and 0.031, respectively, Fig 3A and B).
In particular, we were able to measure urine meprin A in
one patient with KD who initially responded to treatment, but
whosediseaserecurred5.5 monthsafterinitialpresentation.We
observed recurrent elevation of urine meprin A associated with
the relapse of Kawasaki disease (Fig 3C). Likewise, we found
that patients who required repeat treatment with intravenous
gammaglobulin due to the lack of initial clinical response had
signiﬁcantly higher levels of ﬁlamin C at presentation than
patientswhorespondedtoinitialtherapy(mean64vs.20ng/ml,
two-tailed t-test p¼0.0015, Fig 3D).
Encouraged by these ﬁndings, we sought to extend the
validation of meprin A and ﬁlamin C to an independent cohort
of patients. Consequently, we obtained archived specimens
Research Article www.embomolmed.org
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Table 2. Final diagnosis of the 107 study patients
Final diagnosis Number of patients
Kawasaki disease 53
Viral syndrome 33
Adenovirus 6
Serum sickness 3
Pyelonephritis 2
group A streptococcal pharyngitis 2
Cytomegalovirus 1
Epstein-Barr virus 1
Group A streptococcal pharyngitis 1
Lyme disease 1
Otitis media 1
Pneumonia 1
Respiratory syncytial virus 1
Systemic arthritis 1
212  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 210–220collected from patients with Kawasaki disease that would be
available for immediate study. Because urine specimens were
notavailable,weobtained112serumspecimensofpatientswith
KD, collected as part of the recent Paediatric Heart Network
study, andcompared themtopatients initiallysuspected tohave
KD but ultimately diagnosed with non-KD febrile illnesses
(Fig 2E and F). Using ELISAs, we found that both meprin A and
ﬁlamin C were signiﬁcantly elevated in the serum of patients
with KD as compared to non-KD controls (mean ﬁlamin C of
217 vs. 6.6ng/ml, and mean meprin A of 1363 vs. 14.8ng/ml,
respectively, two-tailed t-test p¼1.2E 7 and 3.9E 4, respec-
tively, Supporting Information Table 4).
Since meprin A is a protease that regulates a variety of
immunecytokines, we investigated thepotential involvement of
www.embomolmed.org Research Article
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Figure 1. PatientswithKawasakidiseaseexhibit auniqueurine proteomethat isdistinct from patients withoutKD orcommonlypresenturinaryproteins.
A. Heatmap of the 15 individual urinary proteomes (columns) showing the results of Bayesian analysis of the top 10 proteins (rows) that are detected in patients
with KD as compared to those without. The top 5 proteins that are detected in patients without KD as compared to those with KD are shown for comparison.
Blue-to-red colour gradient represents the number of MS/MS spectra (spectral count) that corresponds to urinary protein abundance.
B. Western immunoblot analysis of meprin A and filamin C in urine, demonstrating enrichment of meprin A and filamin C in the urine of patients with KD as
comparedtopatientswithoutKD.NotethatmeprinAandfilaminCaredetectedpredominantly aspartial-lengthisoforms,withapparentmolecularweightsof
35 and 80kDa, respectively. Albumin serves as the loading control.
EMBO Mol Med (2012) 5, 210–220  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 213meprinAinthepathogenesisofKawasakidiseaseusingamouse
model of coronary arteritis that reproduces several features of
KD (Lehman et al, 1988). In particular, moribund mice develop
systemic mononuclear vasculitis that leads to myocarditis,
aortitis and coronary arteritis with intimal proliferation,
characteristic of Kawasaki disease.Using immunohistochemical
analysis, we found that meprin A was enriched in the vascular
lesions of mice with coronary arteritis but not in control
mice using speciﬁc meprin A antibodies (Fig 4A–H). Likewise,
we found that levels of circulating meprin A and ﬁlamin C were
signiﬁcantly elevated in the serum of mice with coronary
arteritis as compared to control mice (mean 4.7 vs. 0.3ng/ml,
and 107.2 vs. 1.4ng/ml, two-tailed t-test p¼0.0053 and
0.00098, respectively, Fig 4I and J).
DISCUSSION
Kawasaki disease, an acute idiopathic vasculitis of children,
causes signiﬁcant morbidity and mortality if not diagnosed
and treated expeditiously. The use of clinical algorithms in
combination with echocardiography has improved the accuracy
of diagnostic evaluations of Kawasaki disease. In conjunction
with prompt treatment, this has led to signiﬁcant reductions in
mortality and complications from coronary aneurysms. How-
ever, major diagnostic challenges remain because the clinical
criteria used to diagnose KD are not speciﬁc for this condition,
and a signiﬁcant subset of children with KD lacks several of the
cardinal manifestations of the disease.
Several studies have sought to identify biomarkers of this
condition with the goal of improving the diagnostic accuracy of
evaluations of possible KD. Acute phase reactants such as
peripheral blood white cell count, ESR and CRP levels are the
most clinically useful. However, these markers remain inade-
quate in terms of their speciﬁcity and sensitivity (Huang et al,
2010; Xiu-Yu et al, 2010), as conﬁrmed in our study (Fig 2C and
D). Recent attempts to identify improved diagnostic markers,
such as osteoprotegerin, natriuretic peptide and vascular
endothelial growth factor produced limited improvements,
likely as a result of insufﬁcient speciﬁcity for the distinct
immune mechanisms that characterize KD (Ebata et al, 2011;
Kaneko et al, 2011; Simonini et al, 2005).
Research Article www.embomolmed.org
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Figure 2. Patients with Kawasaki disease but not
those with mimicking conditions have
significantly elevated serum and urine levels of
meprin A and filamin C, which exhibit superior
diagnostic performance in a blinded study of
patients suspected of KD.
A,B. Dotplots of urine concentrations measured
using specific ELISAs of meprin A (A) and filamin
C( B) in a blinded case-control study of patients
suspected of KD, demonstrating significantly
elevated concentrations of meprin A and fila-
min C in patients with KD (red) as compared to
those with non-KD conditions (green) and
patients with KD upon receiving IVIg treatment
(blue). p¼2.0E 8 and 1.3E 17 for filamin C
and meprin A, respectively. Horizontal bars
represent means for each comparison group.
Note the logarithmic scale of meprin A and
filamin C concentrations.
C. Receiver operating characteristics of urine
meprin A (red) and filamin C (green), as com-
pared to common markers, ESR (dashed black)
and blood CRP (solid black).
D. Receiver operating characteristic area under
the curve (AUC) values and their 95% confi-
denceintervals(CI)forthemeasureddiagnostic
markers.
E,F. Dotplots of serum concentrations measured
using specific ELISAs of meprin A (E) and filamin
C( F) in patients with KD (red) as compared to
patients with non-KD mimicking conditions
(green). p¼1.2E 7 and 3.9E 4 for filamin C
and meprin A, respectively.
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developed mass spectrometry approaches, we sought to
discover more accurate and sensitive diagnostic markers. We
analysed the urine proteomes of patients with KD as compared
to those initially suspected to have KD but ultimately proved
to have other febrile illnesses. This allowed us to construct a
molecular pathophysiological proﬁle of Kawasaki disease
comprising of over 190 candidate KD markers (Fig 1 and
Supporting Information Table 1). These molecules include
potential markers of endothelial and myocardial injury (talin,
ﬁlamin, desmoglein, obscurin and titin), leukocyte activation
(AMICA1, CAECAM, CXCL12, GDF15 and LAIR1), pathogen
immune recognition (DMBT1, ABCB9) and cytokine regulation
(CSMD3, meprin A).
We found several immune regulatory molecules to be
uniquely present in the urine of patients with KD. Among these
was meprin A, a metalloprotease that functions in the activation
and degradation of inﬂammatory cytokines, which have been
implicated in the pathogenesis of KD, including IL-1 and IL-6
(Chow et al, 1993; Herzog et al, 2005). Similarly, DMBT1, also
known as muclin or gp340, is an innate immune scavenger
receptor that recognizes a variety of bacterial and viral antigens
(Madsen et al, 2010). Finally, ABCB9, also known as TAPL, is a
transporter that functions in immune antigen presentation
(Bangert et al, 2011). Many of the identiﬁed KD marker
candidates, if properly validated as we have done here for
meprin A and ﬁlamin C, may represent not only diagnostic
markers, but also novel therapeutic targets. Taken together, the
identiﬁed proteomes, including both raw and processed data,
available openly at Peptide Atlas (http://www.peptideatlas.
org), and containing 190 novel candidate KD markers listed in
Supporting Information Tables 1 and 2, provide a molecular
physiological proﬁle of Kawasaki disease. Interactions of the
components of the innate and adaptive immune responses
in patients implicated by this molecular proﬁle may further
elucidate pathogenic mechanisms mediating Kawasaki disease.
Importantly, using a prospective, blinded study of patients
with suspected KD, we conﬁrmed that ﬁlamin C and meprin A
are signiﬁcantly elevated in the serum and urine of patients with
KD but not those with a variety of mimicking conditions (Fig 2).
Both markers demonstrated superior diagnostic performance
as compared to the currently used laboratory tests (Fig 2). In
contrast to ﬁlamin A and ﬁlamin B, the high expression of
ﬁlamin C in myocytes (Bonnemann et al, 2003) suggests that
ﬁlamin C represents a sensitive and speciﬁc marker of the
subclinical myocarditis that accompanies KD. Indeed, markers
of frank cardiomyocyte injury such as troponin have not been
foundtocorrelatewithclinicalorechocardiographicevidenceof
myocarditis (Checchia et al, 2001; Sato et al, 2011). In addition,
elevated levels of ﬁlamin C in patients with KD who did not
respond to initial therapy as compared to those with complete
response suggest that ﬁlamin C is a marker of Kawasaki disease
activity (Fig 3D). Meprin A and ﬁlamin C were also elevated
in patients with incomplete presentations of KD, suggesting
that these markers may be used to improve the diagnosis of
incomplete presentations of KD.
Similarly, meprin A is a protease that regulates a variety of
inﬂammatory cytokines, including biologically active IL-1b,
a key pro-inﬂammatory cytokine (Herzog et al, 2005),
polymorphisms of which have been associated with resistance
to treatment of KD (Weng et al, 2010). Thus, meprin A
may contribute to the initiation, propagation or compensatory
www.embomolmed.org Research Article
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Figure 3. Urine filamin C and meprin A correlate
with disease activity in patients with KD.
A,B. Urine meprin A (A) and filamin C (B) levels in
five patients with KD, as measured in matched
specimens collected at diagnosis, 24–48h after
treatment, and 1 month after complete clinical
response.
C. Urine meprin A level in one patient who
experienced recurrence of KD 5.5 months after
initial presentation.
D. Scatter plot showing urine filamin C levels in
patients who responded to initial therapy (red,
responders) versus those who required repeat
treatment (green, non-responders). p¼0.0015.
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meprin A to the pathophysiology of KD are emphasized by its
enrichment in the coronary lesions in a mouse model of KD
(Fig 4) and correlation with disease severity in patients with
KD (Fig 3). Though meprin A is expressed by the kidney and
leukocytes (Bond et al, 2005), meprin A elevations in the urine
of patients with KD do not appear to relate to the presence of
pyuria that can accompany KD (Supporting Information Fig 2).
Also, elevations of urine meprin A or ﬁlamin C in patients
suspected of Kawasaki disease do not appear to correlate
to acute phase reactants such as ESR or CRP (Supporting
Information Figs 3–6).
The mechanisms by which these discovered KD markers
accumulate in the urine of patients and their relationship to the
pathophysiology of KD are important directions for future work.
We attempted to mitigate the stochastic effects of instrumental
sampling in proteomics by using Bayesian statistics, but cannot
rule out the possibility that the discovered molecular patho-
physiological proﬁle of KD may both omit signiﬁcant and
include irrelevant proteins. In addition, meprin A and ﬁlamin C
will require further studies in patients with renal or urologic
disease or extreme dehydration, and development of their
clinical-grade assays will require normalization for potential
variations in total urine protein concentration. Ultimately,
testing of meprin A and ﬁlamin C in multi-institutional,
interventional studies of KD will be necessary for their clinical
implementation.
In summary, the work presented here opens many potential
approaches for improving the diagnosis of Kawasaki disease,
elucidating its pathophysiology and directing therapy. In
particular, validation of meprin A and ﬁlamin C as speciﬁc
and sensitive markers of Kawasaki disease using commonly
available ELISAs enables their clinical use to improve the
accuracy and timeliness of diagnosis of KD. In addition, the
described molecular physiological proﬁles and validated
diagnostic markers should allow for a biological classiﬁcation
of Kawasaki disease that will lead to improved patient
stratiﬁcation and allow for individualized treatment, as also
recently suggested by Cohen and colleagues (Ling et al,
2011). More broadly, the approach presented here advances a
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Figure 4. Meprin A is enriched in coronary artery
lesions in a mouse model of Kawasaki disease.
A,B. Micrographs of hematoxylin and eosin-stained
sectionsoftheaortic root andcoronaryarteries
of control (A) and LCWE-injected mice (B)
demonstrating severe aortitis with intimal
proliferation leading to concentric obstruction
in the LCWE-injected but not control animals.
Arrows point to the normal (A) and diseased (B)
coronary arteries.
C,D. Micrographs of meprin A immunohisto-
chemistry-stained inset areas of the sections of
coronary arteries demonstrating enrichment of
meprin A in the mononuclear infiltrates of
coronary arteries in LCWE-injected (D) but not
control (C) animals.
E,F. Micrographs of isotype control-stained
sections of coronary arteries in LCWE-injected
(F) and control (E) mice.
G,H. High-magnification micrographs of the inset
areas of meprin A (G) and isotype control-
strained (H) sections of the coronary arteries in
LCWE-injected mice.
I,J. Serum levels of meprin A (I) and filamin (J) are
elevated in the LCWE-injected (red) as com-
pared to control (green) mice. Scale bar is
250mM.
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translation to clinical practice, with applications in a wide
variety of common and rare human conditions (Kentsis, 2011;
Kentsis et al, 2009).
MATERIALS AND METHODS
Study participants
The study was conducted over a 39 month period beginning in
January 2009 at a tertiary care paediatric hospital and approved by
the Boston Children’s Hospital Committee on Clinical Investigation.
Patients younger than 18 years of age who were being evaluated for
possible Kawasaki disease were enrolled according to clinical history
and physical examination. Patients were excluded if they had pre-
existing neoplastic, renal or urologic disease or were pregnant. The
paediatric emergency medicine or rheumatology physicians obtained
written consent from caregivers and assent for children older than
7 years of age. Informed consent was obtained from all subjects and
the research conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report.
Study design
Our study was conducted in two phases. For the discovery phase, urine
samples from six patients with Kawasaki disease, including both
patients with and without coronary artery ectasia, were compared
with urine samples from six patients initially suspected of Kawasaki
disease but with the final diagnosis of febrile illnesses mimicking
Kawasaki disease (two with non-specific viral syndromes, three with
adenovirus and one with pyelonephritis). We also included in the
discovery analysis three intra-individual control specimens collected
from patients with Kawasaki disease after completing treatment and
resolution of symptoms.
The validation phase was comprised of the analysis of two
independent cohorts.The first cohort was based on patients evaluated
for possible Kawasaki disease, but before the determination of the
final diagnosis. The second cohort utilized serum specimens collected
as part of the Pediatric Heart Network Study of Kawasaki disease
(Newburger et al, 2007).
For all study patients, urine was collected as clean-catch samples
at the time of clinical evaluation. Specimens were cleared by
centrifugation according to standard methods, and were labelled
with a study number such that all analysis was blinded. Specimens
were stored at  808C within 6h of collection. Blood specimens
for serum collection were clotted and centrifuged according to
standard methods, with the serum stored at  808C within 30min
of collection.
Outcome measures
Final diagnosis was determined by paediatric rheumatology physi-
cians of a single tertiary care institution according to published
diagnostic criteria for Kawasaki disease (Newburger et al, 2004). For
patients with at least 4 days of fever, the diagnosis of Kawasaki
disease was established using either four or more principal clinical
criteria for Kawasaki disease or a coronary artery z-score of 2.5 or
more for the proximal right coronary artery or the left anterior
descending coronary artery, as measured by two-dimensional
echocardiography (Newburger e ta l ,2 0 0 4 ) .F o rp a t i e n t sw i t h
incomplete presentations of KD meeting <4 diagnostic clinical criteria,
the diagnosis of KD was established according to the American Heart
Association Guidelines (Newburger et al, 2004). For patients enrolled
as part of the Pediatric Heart Network Study, the final diagnosis
was determined using identical criteria (Newburger et al, 2007). For
patients initially suspected of KD but ultimately diagnosed with non-
KD febrile illnesses, the diagnosis of KD was excluded by the lack of
four primary diagnostic criteria of KD. For patients with <4 primary
diagnostic criteria, the diagnosis of KD was excluded by the absence of
elevations of CRP or ESR, or by the absence of supplemental laboratory
criteria, as published (Newburger et al, 2004). For patients who were
found to not have Kawasaki disease, a diagnosis of non-specific viral
syndrome was assigned based on clinical evaluation, if no specific
pathogen was identified. For patients who were not hospitalized, the
outcome was confirmed by telephone 6–8 weeks after evaluation
using scripted questions or from medical chart review to ascertain
whether the patient had any subsequent medical care. All studied
patients received a final outcome. Clinical and laboratory data was
tracked using standardized case report forms.
Urine proteome analysis
For the discovery of candidate markers of Kawasaki disease, thawed
5ml urine aliquots were fractionated using ultracentrifugation,
protein precipitation, SDS–PAGE, and reverse-phase liquid chromato-
graphy, as described in detail (Kentsis et al, 2009). Individual urine
protein fractions were subjected to liquid chromatography tandem
mass spectrometry using a nanoflow HPLC system (Eksigent, Dublin,
CA) coupled to the hybrid linear ion trap-Fourier transform ion
cyclotron resonance mass spectrometer (LTQ FT Ultra, Thermo
Scientific, Waltham, MA). For each MS/MS spectrum, the 200 most
intense peaks were extracted and searched against the human
International Protein Index database (version 3.69, http://www.ebi.a-
c.uk/IPI) by using MASCOT (version 2.1.04, Matrix Science). Assessment
of identification accuracy was carried out by searching a decoy
database composed of reversed protein sequences of the target IPI
database (Elias & Gygi, 2007). Only proteins identified on the basis of
two or more unique peptides were included in the analysis, at a false
discovery rate of <1% at the peptide level. Analysed individual
urine proteomes are openly available at Peptide Atlas (http://
www.peptideatlas.org).
Laboratory measurements and filamin C and meprin A
immunoassays
Blood chemistry, immunoassay tests such as CRP and urine creatinine
measurements were performed using the COBAS and Modular P
systems (Roche Diagnostics). ESRs were measured using the Excyte 40
automated analyser (Vital Diagnostics). Urinalysis measurements were
performed using the Clinitek Atlas automated analyser (Siemens).
Concentrations of filamin C and meprin A were measured using
enzyme-linked immunosorbent assays (USCN Life Science, Wuhan,
China). The lowest detection limits of the assays were 0.1 and
0.06ng/ml, respectively, with the coefficient of variation for the
quality control specimens of <10% for both assays. Specificity was
confirmed using purified synthetic proteins, and apparent immuno-
assay interference effects in urine were corrected by serial dilution.
For Western immunoassays, 1ml urine aliquots were precipitated by
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final concentration, and incubating on a rotating shaker at 48C
overnight. Precipitated proteins were sedimented by centrifugation at
16,000g for 20min at 48C, washed twice with cold acetone, air-dried,
and dissolved in 0.1ml of RIPA buffer. Protein concentrations were
determined by using bicinchoninic acid-copper reduction (Bio-Rad)
and 30mg protein aliquots were denatured in Laemmli buffer at
958C for 5min, resolved using SDS–PAGE, transferred to PVDF
membrane (Pierce), blocked and probed by using primary antibodies
against meprin A (clone 364312, R&D Systems) or filamin C
(clone A01, Abnova). Bound antibodies were detected by using
horseradish peroxidase-conjugated secondary antibodies, SuperSignal
West Dura reagent (Pierce), and the ImageQuant LAS 4000
chemiluminescence imaging system (GE Healthcare), according to
manufacturer’s instructions.
Analysis of murine model of coronary arteritis and meprin A
immunohistochemistry
We used an established murine model of coronary arteritis based on
intraperitoneal injection of the cell wall extract of group B
Lactobacillus casei (LCWE) (Lehman et al, 1988). Group B L. casei were
grown and its cell wall extract was prepared as described (Schulte
et al, 2009). Briefly, 6-week old C57/BL6 mice were injected with
250mg of LCWE in phosphate buffered saline (PBS) or with saline
alone. Fourteen days later, mice were sacrificed, and coronary arteries
were identified in serial sections (7mm) fixed with formalin and
stained with hematoxylin and eosin. For the immunohistochemical
analysis, sections were pre-treated with 0.3% hydrogen peroxide in
PBS for 30min. Meprin A (clone F-20, Santa Cruz Biotechnology, Santa
Cruz, CA) or isotype control antibody (goat serum, Santa Cruz
Biotechnology) was applied in 0.5% bovine serum albumin in PBS at
1:100 for 1h. Slides were then washed and biotinylated anti-goat
horseradish peroxidase conjugated secondary antibody (Vector Lab,
Burlingame, CA) was applied at 1:500 for 30min, washed and stained
with streptavidin conjugated horseradish peroxidase (BD Biosciences,
San Diego, CA) at 1:1000 for 30min. Immunohistochemical staining
was detected using the SK-4100 DAB kit, as per manufacturer’s
instructions (Vector Lab).
Statistical analysis
Discovery urine proteomes were assembled by parsimonious protein
grouping, as described (Kentsis et al, 2009), with the individual
peptide counts summed to calculate protein spectral counts. We used
Bayesian statistics, as implemented in QSpec (Choi et al, 2008), to
analyse protein spectral counts to identify proteins that are
statistically significantly enriched at the 1% false discovery threshold
in samples from patients with Kawasaki disease, but not in samples
from non-Kawasaki disease patients or intra-personal control samples
of patients with Kawasaki disease after completion of treatment.
Observed peptide spectral counts were normalized to the lengths of
the corresponding expected proteins. No assumptions about sample
independence were made, allowing for inclusion of paired specimens,
which significantly improve discovery yields (Kentsis et al, 2010). ROCs
and multivariate linear regression models were calculated using
standard methods (STATA, version 10.1, StataCorp). All statistical tests
were two-tailed using comparisons of log-transformed measurements.
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The paper explained
PROBLEM:
In spite of years of intensive study, accurate diagnosis and
understanding of the causes of Kawasaki disease remain elusive.
As a consequence, delayed or inaccurate diagnosis causes
significant complications and long-term injury and hinders the
development of improved therapies.
RESULTS:
Using recently developed techniques for analysing thousands of
protein molecules in the urine of patients with Kawasaki disease,
and those with conditions that routinely mimic Kawasaki
disease, we identified signatures of distinct biological processes
that are associated with Kawasaki disease. Using tests readily
amenable for routine medical use, we found that two discovered
markersofKawasakidisease,meprinAand filaminC, canbeused
to identify patients with Kawasaki disease with excellent
accuracy.
IMPACT:
Development of clinical tests using these markers may improve
thediagnosticaccuracyofevaluationsofchildrenwithsuspected
Kawasaki disease and lead to the development of improved
treatments.
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